ObvioHealth Is Building A New Digital Ecosystem To 'Revolutionize' Trials
Using artificial intelligence and strict data collection protocol, ObvioHealth hopes to digitize clinical trials with the assistance of medical devices and consumer technology.
You may also be interested in...
The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.
A “federated” training method could be used to reduce bias in AI, according to one expert on patient safety.
Cumulus Neuroscience, previously known as BrainWaveBank, announced a £6m financing round to help develop its unique neurological data collection system.